FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to hot flush treatment in mammals, including human. Method involves (3S,5R)-3-aminomethyl-5-methyloctane acid or its pharmaceutically acceptable salt introduced in the patient organism in effective amount.
EFFECT: method provides treatment of moderate and severe vasomotor symptoms, including in post menopause in women, ensured by predominant high activity of the acid as alpha-2-delta ligand.
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS CONTAINING ALPHA-2-DELTA LIGANDS AND SEROTONIN/NORADRENALINE REUPTAKE INHIBITORS | 2004 |
|
RU2320369C2 |
| COMBINATIONS OF ALPHA-2-DELTA-LIGAND WITH SELECTIVE CYCLOIXYGENASE-2 INHIBITOR | 2003 |
|
RU2286151C2 |
| ALPA-2-DELTA LIGAND FOR LOWER URINARY TRACT SYMPTOMS TREATMENT | 2003 |
|
RU2331438C2 |
| METHOD OF TREATMENT OF DISEASES AT MAMMALS | 2004 |
|
RU2344121C2 |
| DERIVATIVES OF CYCLOPROPYL-β-AMINO ACID | 2004 |
|
RU2312853C2 |
| SALTS AND CRYSTALLINE FORMS | 2014 |
|
RU2654855C2 |
| QUINOLINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | 2008 |
|
RU2460727C2 |
| HCV-ACTIVE 4'-ASIDONUCLEOSIDES | 2011 |
|
RU2556991C2 |
| SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT | 2000 |
|
RU2229289C2 |
